Moderna (MRNA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$241.46-6.55%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
Research Workspace
Put MRNA beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Achieve up to 10% revenue growth in 2026: Comparison needs review.
View ThesisMiddle-of-the-pack quality for its industry.
View QualityMiddle-of-the-pack management execution.
View ManagementExpectations look high — the market is pricing in about 120% growth a year, above the roughly 8% analysts expect, leaving little room for error.
View ValuationThis stock is volatile — it swings about 3% on a typical day and fell roughly 34% in its worst 12-month stretch.
View RiskModerna's cancer pipeline has to keep compounding to justify the price. Revenue growth is slowing sharply from 269% to 2% year over year. The latest quarter came in inline with expectations. The stock trades at 46 times sales versus an 8.8 times peer median. The market is pricing in more growth than we forecast. The primary revenue growth pillar is under pressure. The thesis comparison is not yet verified. Peer multiples imply a price about 135% below where it trades. The thesis is on watch. This read is provisional.
Trailing returns as of 2026-11-05. MRNA is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 23 analysts currently covering MRNA (as of Nov 2026).
Based on 10 Wall Street analysts offering 12-month price targets for MRNA in the last 4 months.
Continue this research
Compare MRNA with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| MRNA Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 3 valuation methods, at three horizons. As of 2026-11-05. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put MRNA next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Legal pressure on patent defense creates financial and operational risk.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-11-05. EPS is implied from price ÷ P/E. Not investment advice.
Current $241.46
The last 12 months of price, then the range of analyst 12-month targets from today’s $241.46.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Threatens: Advance late-stage pipeline with key regulatory approvals
Investors react negatively to melanoma-vaccine trial data, challenging pipeline expectations.
Threatens: Advance late-stage pipeline with key regulatory approvals
Analysis says leaked cancer-vaccine data leave efficacy unclear, increasing pipeline uncertainty.
Threatens: Advance late-stage pipeline with key regulatory approvals
Analyst reaction to a sharp post-results drop highlights doubts about cancer-vaccine data.
Threatens: Advance late-stage pipeline with key regulatory approvals
Coverage frames cancer-vaccine news as negative despite favorable headline results.
Threatens: Advance late-stage pipeline with key regulatory approvals
Reported leak concerns late-stage melanoma vaccine data, but the headline does not establish verified results.
Threatens: Advance late-stage pipeline with key regulatory approvals
Sharp decline amid leaked cancer-vaccine data signals material investor concern about pipeline.
Advances: Advance late-stage pipeline with key regulatory approvals
Nasdaq-100 reentry and NIH cancer-vaccine support improve visibility for pipeline prospects.
